icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
Back grey_arrow_rt.gif
 
 
 
THE PHASE 3 C-EDGE TREATMENT-NAIVE (TN) STUDY OF A 12-WEEK ORAL REGIMEN OF GRAZOPREVIR (GZR, MK-5172)/ELBASVIR (EBR, MK-8742) IN PATIENTS WITH CHRONIC HCV GENOTYPE (GT) 1, 4, OR 6 INFECTION
 
 
  Reported by Jules Levin
 
EASL 2015 April 22-26 Vienna Austria
 
Stefan Zeuzem* 1, Reem Ghalib2, K. R. Reddy3, Paul J. Pockros4, Ziv B. Ari5, Yue Zhao6, Deborah Brown7, Mark DiNubile6, Michael Robertson6, Janice Wahl7, Eliav Barr6, Joan Butterton6 1Goethe University Hospital, Frankfurt, Germany, 2Texas Clinical Research Institute, Dallas, 3University of Pennsylvania, Philadelphia, 4Scripps Translational Science Institute, La Jolla, United States, 5Sheba Medical Center, Ramat Gan, Israel, 6Merck, 7Meck, Whitehouse Station, United States

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif

EASL12.gif

EASL13.gif